Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

Jan Craig Buckner, Patrick A. Burch, Terrence L. Cascino, Judith R. O'Fallon, Bernd W. Scheithauer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalJournal of Neuro-Oncology
Volume36
Issue number1
DOIs
StatePublished - 1998

Fingerprint

Eflornithine
Glioma
Interferon-alpha
Interferons
Neoplasms
Confusion
Chills
Interferon-beta
Myalgia
Radiation Effects
Astrocytoma
Polyamines
Glioblastoma
Neurologic Manifestations
Fatigue
interferon alfa-2a
Fever

Keywords

  • Brain neoplasm
  • Eflornithine
  • Glioma
  • Interferon
  • Phase II

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. / Buckner, Jan Craig; Burch, Patrick A.; Cascino, Terrence L.; O'Fallon, Judith R.; Scheithauer, Bernd W.

In: Journal of Neuro-Oncology, Vol. 36, No. 1, 1998, p. 65-70.

Research output: Contribution to journalArticle

Buckner, Jan Craig ; Burch, Patrick A. ; Cascino, Terrence L. ; O'Fallon, Judith R. ; Scheithauer, Bernd W. / Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. In: Journal of Neuro-Oncology. 1998 ; Vol. 36, No. 1. pp. 65-70.
@article{ebd93979ce7545b6908d3277c3682c9e,
title = "Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma",
abstract = "Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24{\%}) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.",
keywords = "Brain neoplasm, Eflornithine, Glioma, Interferon, Phase II",
author = "Buckner, {Jan Craig} and Burch, {Patrick A.} and Cascino, {Terrence L.} and O'Fallon, {Judith R.} and Scheithauer, {Bernd W.}",
year = "1998",
doi = "10.1023/A:1005870329601",
language = "English (US)",
volume = "36",
pages = "65--70",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

AU - Buckner, Jan Craig

AU - Burch, Patrick A.

AU - Cascino, Terrence L.

AU - O'Fallon, Judith R.

AU - Scheithauer, Bernd W.

PY - 1998

Y1 - 1998

N2 - Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.

AB - Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.

KW - Brain neoplasm

KW - Eflornithine

KW - Glioma

KW - Interferon

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=0031776472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031776472&partnerID=8YFLogxK

U2 - 10.1023/A:1005870329601

DO - 10.1023/A:1005870329601

M3 - Article

C2 - 9525827

AN - SCOPUS:0031776472

VL - 36

SP - 65

EP - 70

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -